Abstract:
A training system is disclosed. The training system includes a server. The server includes a processor, data storage, a data input/output interface, and a voice interface. The data input/output interface is configured to provide a web-based interface to a data terminal and to receive, from the data terminal and via the web-based interface, both an identifier identifying at least one voice terminal and at least one response. The voice interface is configured to transmit at least one audio test signal corresponding to at least one audio test to the at least one voice terminal. The response is a response to the at least one audio test. In one embodiment, the voice terminal and the data terminal are combined in a single device.
Abstract:
There are provided inter alia compounds of formula (I): wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.
Abstract:
There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
Abstract:
There is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, including all tautomers thereof, compositions comprising the same, use of said compound and compositions for treatment, in particular for the treatment of asthma and COPD, and processes for the preparation of said compound.
Abstract:
The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
Abstract:
There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
Abstract:
Novel flavonoid compounds having anti-oxidant activity are described. Formula 1. The compounds have been shown to exhibit anti-oxidative properties in biological systems and their utility in a sunscreen or skincare composition or to treat conditions involving oxidative damage, especially curative or prophylactic treatment of Alzheimer's disease or ischaemia-reperfusion injury, is described.
Abstract:
A microwave antenna suitable for cardiac ablation, in particular for catheter ablation, and a method for making such an antenna. The antenna comprises a transmission line having an inner conductor, an outer conductor, and a dielectric insulator to provide insulation between the inner and outer conductors. An energy emitting antenna element is located at the distal end of the transmission line. The antenna element has an inner conductor which is electrically coupled to the inner conductor of the transmission line, and, around the inner conductor, a sheath of dielectric insulator continuous with the insulator of the transmission line. At its distal end, a hollow metallic cap is electrically connected to the inner conductor, surrounding a length of the insulator.
Abstract:
The present invention relates to a process for selectively removing undesired oligosaccharides from aqueous mixtures such as plant processing waste products, including soy whey and other vegetable wheys, using an ultrastabilized large pore, hydrophobic zeolite Y. The resulting solution, which contains isoflavones and digestible sugars such as glucose, fructose and sucrose, can serve as the basis for a nutritious new product.
Abstract:
The present invention provides a process using zeolites for recovering isoflavones and removing undesired oligosaccharides from aqueous mixtures, such as soy whey and other plant processing waste products. The aqueous mixture is treated with a large pore hydrophobic zeolite, such as zeolite Beta, to remove isoflavones, followed by treatment with an ultrastabilized, hydrophobic zeolite Y, such as CBV-901 or HiSiv™ 4000, to remove the undesired oligosaccharides raffinose and stachyose. The recovered isoflavones and digestible sugars, glucose, sucrose, and fructose, are useful in food products.